Get started
Work

76MO Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial

Year: 2022
Type: article
Study design: Clinical Trial
DOI: 10.1016/j.annonc.2022.10.112
Authors: J.O. Park, D.T. Wai Meng, A. Hollebecque, M. Borad, L. Goyal, A. Schram, P. Cassier, S.D. Kamath, E. Dotan, R. Kim, V. Sahai, C-Y. Liao, M. Millward, D. Roda Perez, R. Blakesley, B. Wolf, V. Subbiah, R.K. Kelley, D-Y. Oh
Institutions: Samsung Medical Center, Sungkyunkwan University, National Cancer Centre Singapore, Institut Gustave Roussy, Mayo Clinic, Mayo Clinic in Arizona, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Centre Léon Bérard, Cleveland Clinic, Fox Chase Cancer Center, University of South Florida, Moffitt Cancer Center, University of Michigan, University of Chicago, The University of Western Australia, Linear Clinical Research, Hospital Clínico Universitario de Valencia, Relay Therapeutics (United States), The University of Texas MD Anderson Cancer Center, University of California, San Francisco, Seoul National University Hospital
Language: English
Subfield: Surgery
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4310754092
FWCI: 1.491
Cites:
Cited by: 7
Related to: 10